Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in Septebmer 2017 at the end of the 10-year period of market exclusivity.
On 13 November 2002, orphan designation (EU/3/02/121) was granted by the European Commission to medac Gesellschaft für klinische Spezialpräparate mbH, Germany, for 5-aminolevulinic acid hydrochloride for the intra-operative photodynamic diagnosis of residual glioma.
5-aminolevulinic acid hydrochloride has been authorised in the EU as Gliolan since 7 September 2007.
5-aminolevulinic acid hydrochloride
|Disease / condition||
Intra-operative photodynamic diagnosis of residual glioma
|Date of decision||
|Orphan decision number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.